Immucell ICCC
NASDAQ ICCC
$11.42 +0.67 (+6.23%)
At close: Nov 16, 2026 · 4:00 PM EST

Immucell (ICCC) Gains (Losses) on Sale of Assets & Investments (2017 - 2026)

Updated

Immucell (ICCC) recorded Gains (Losses) on Sale of Assets & Investments of $4,264 in Q1 2026, compared with -$4,865 a year earlier.

Analysis

Immucell (ICCC) Gains (Losses) on Sale of Assets & Investments (2017 - 2026) Analysis & Trends

For FY2023, Immucell reported Gains (Losses) on Sale of Assets & Investments of -$8,099.

  • Across earlier years, Gains (Losses) on Sale of Assets & Investments came in at $7,334 in FY2022.
  • Quarterly Gains (Losses) on Sale of Assets & Investments has ranged from -$62,319 in Q3 2025 to $7,128 in Q2 2025 over the past five years.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Gains on Sales (Qtr)
1 Eli Lilly 1,276.89 Bn 1,250.50 Bn 20.46 Bn -
2 Johnson & Johnson 681.31 Bn 601.18 Bn 17.30 Bn -
3 AbbVie 520.63 Bn 488.64 Bn 13.12 Bn -
4 Merck 357.22 Bn 320.16 Bn 13.19 Bn -
5 Novartis Ag 310.90 Bn 284.14 Bn - -
6 Astrazeneca 285.12 Bn 258.77 Bn 13.26 Bn -
7 Amgen 250.23 Bn 201.89 Bn 7.58 Bn -
8 Gilead Sciences 207.56 Bn 182.67 Bn 6.73 Bn -
9 Pfizer 164.42 Bn 111.77 Bn 12.56 Bn -
10 Immucell 102.43 Mn 75.03 Mn 3.56 Mn -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2026 4,264.00
Sep 30, 2025 -62,319.00
Jun 30, 2025 7,128.00
Mar 31, 2025 -4,865.00
Jun 30, 2024 -14,557.00
Jun 30, 2023 77.00
Mar 31, 2023 -8,243.00
Sep 30, 2018 700,000.00
Jun 30, 2018 75.00
Dec 31, 2017 -1,340.00
Sep 30, 2017 8,045.00
Jun 30, 2017 -679.00
API Access

Immucell Gains (Losses) on Sale of Assets & Investments API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=non-operating-investment-income&ticker=ICCC&period=max&api_key=YOUR_API_KEY